Cardiovascular Disease Doctors in Maple Grove, MN Accepting Medicare

1 Cardiovascular Disease doctors found. Showing 1 - 1

Dr. Dominic John Allocco, MD Internal Medicine - Cardiovascular Disease Medicare: Not Enrolled in Medicare Practice Location: 1 Scimed Pl, Maple Grove, MN 55311 Phone: 763-494-1985

News Archive

Algal DHA supplementation benefits during pregnancy and infancy

Positive results from clinical trials exploring algal DHA supplementation during pregnancy and infancy were presented this week at the 10th Congress of the International Society for the Study of Fatty Acids and Lipids (ISSFAL) – an international scientific society focused on research of dietary fats, oils and lipids.

Research shows close similarities of canine models of human rare disorders

Professor Hannes Lohi's research group at the University of Helsinki has discovered three novel canine genes for Caffey, Raine and van den Ende-Gupta syndromes. Research reveals close similarities of the canine models of human rare disorders and highlights the potential of comparative research approach for the development of rare disease diagnostics and treatments.

Technique that cleared mouse of HIV-like virus sparks hope for new therapy

In a breakthrough, Australian researchers have developed a method to boost the immune system. This technique is seen to be capable of clearing an "HIV-like" infection from a mouse. This could in future lead to a cure for HIV and other chronic viral infections in humans. The findings from Melbourne's Walter and Eliza Hall Institute are centred on a naturally occurring cell signalling hormone called interleukin-7 (IL-7).

Alkermes announces results from phase 3 clinical trial of aripiprazole lauroxil in patients with schizophrenia

Alkermes plc today announced positive topline results from a randomized, double-blind, placebo-controlled phase 3 clinical trial of aripiprazole lauroxil in patients with schizophrenia. Patients treated once monthly with either 441 mg or 882 mg of aripiprazole lauroxil demonstrated statistically significant reductions from baseline in Positive and Negative Syndrome Scale (PANSS) total scores at week 12, compared to placebo (p<0.001 aripiprazole lauroxil 441 mg, p<0.001 aripiprazole lauroxil 882 mg), which was the prespecified primary endpoint in the study. Based on the positive results from this phase 3 study, Alkermes plans to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in the third quarter of 2014.

Read more Medical News

› Verified 7 days ago